Kim Song-Jung, Abdellatif Maha, Koul Sharat, Crystal George J
Section of Cardiology, Advocate Illinois Masonic Medical Center, Chicago, IL 60657, USA.
Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H130-5. doi: 10.1152/ajpheart.00298.2008. Epub 2008 May 2.
Chronic treatment with insulin-like growth factor I (IGF-I) improves contractile function in congestive heart failure and ischemic cardiomyopathy. The present study investigated the effect of chronic treatment with IGF-I on intrinsic myocyte function and the role of the phosphatidylinositol (PI)3-kinase-Akt-sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA)2a signaling cascade in these responses. Myocytes were isolated from 23 adult rats and cultured with and without IGF-I (10(-6) M). After 48 h of treatment, myocyte function was evaluated. IGF-I increased contractile function (percent contraction, 7.7 +/- 0.3% vs. 4.5 +/- 0.3%; P < 0.01) and accelerated relaxation time (time for 70% relengthening, 81 +/- 4 vs. 106 +/- 5 ms; P < 0.05) compared with untreated myocytes [control (Con)]. The enhanced function was associated with an increase in Ca(2+) transients assessed by fura-2 (340/380 nm; IGF-I, 0.42 +/- 0.02 vs. Con, 0.25 +/- 0.01; P < 0.01). The PI3-kinase inhibitor LY-249002 (10(-9) M) abolished the enhanced function caused by IGF-I. IGF-I increased both Akt and SERCA2a protein levels 2.5- and 4.8-fold, respectively, compared with those of Con (P < 0.01); neither phospholamban nor calsequestrin was affected. To evaluate whether the SERCA2a protein was directly mediated by Akt-SERCA2a signaling, IGF-I-induced changes in the SERCA2a protein were compared in myocytes transfected with adenovirus harboring either constitutively active Akt [multiplicity of infection (MOI), 15] or dominant negative Akt (dnAkt; MOI, 15). The ability of IGF-I to upregulate the SERCA2a protein in myocytes transfected with active Akt was absent in dnAkt myocytes. Taken together, our findings indicate that chronic treatment with IGF-I enhances intrinsic myocyte function and that this effect is due to an enhancement in intracellular Ca(2+) handling, secondary to the activation of the PI3-kinase-Akt-SERCA2a signaling cascade.
胰岛素样生长因子I(IGF-I)的长期治疗可改善充血性心力衰竭和缺血性心肌病的收缩功能。本研究调查了IGF-I长期治疗对心肌细胞内在功能的影响,以及磷脂酰肌醇(PI)3激酶-Akt-肌浆网Ca(2+)-ATP酶(SERCA)2a信号级联在这些反应中的作用。从23只成年大鼠中分离出心肌细胞,并在有或无IGF-I(10(-6)M)的情况下进行培养。治疗48小时后,评估心肌细胞功能。与未处理的心肌细胞[对照组(Con)]相比,IGF-I增加了收缩功能(收缩百分比,7.7±0.3%对4.5±0.3%;P<0.01)并缩短了舒张时间(70%再延长时间,81±4对106±5毫秒;P<0.05)。功能增强与用fura-2评估的Ca(2+)瞬变增加有关(340/380纳米;IGF-I,0.42±0.02对Con,0.25±0.01;P<0.01)。PI3激酶抑制剂LY-249002(10(-9)M)消除了IGF-I引起的功能增强。与Con相比,IGF-I分别使Akt和SERCA2a蛋白水平增加了2.5倍和4.8倍(P<0.01);受磷蛋白和肌集钙蛋白均未受影响。为了评估SERCA2a蛋白是否直接由Akt-SERCA2a信号介导,在转染了携带组成型活性Akt[感染复数(MOI),15]或显性负性Akt(dnAkt;MOI,15)的腺病毒的心肌细胞中,比较了IGF-I诱导的SERCA2a蛋白变化。在dnAkt心肌细胞中,IGF-I上调转染活性Akt的心肌细胞中SERCA2a蛋白的能力缺失。综上所述,我们的研究结果表明,IGF-I的长期治疗可增强心肌细胞的内在功能,并且这种作用是由于PI3激酶-Akt-SERCA2a信号级联激活后细胞内Ca(2+)处理增强所致。